EA200700876A1 - AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2 - Google Patents

AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2

Info

Publication number
EA200700876A1
EA200700876A1 EA200700876A EA200700876A EA200700876A1 EA 200700876 A1 EA200700876 A1 EA 200700876A1 EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A1 EA200700876 A1 EA 200700876A1
Authority
EA
Eurasian Patent Office
Prior art keywords
angiopoetin
specifically binding
agents specifically
antibodies
fragments
Prior art date
Application number
EA200700876A
Other languages
Russian (ru)
Other versions
EA011866B1 (en
Inventor
Джонатон Даниел Олайнер
Кевин Грэхэм
Original Assignee
Амджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Амджен Инк. filed Critical Амджен Инк.
Publication of EA200700876A1 publication Critical patent/EA200700876A1/en
Publication of EA011866B1 publication Critical patent/EA011866B1/en

Links

Abstract

Раскрыты специфические связывающие агенты, такие как полностью человеческие антитела, которые связывают ангиопоэтин-2. Раскрыты также фрагменты тяжёлых цепей, фрагменты лёгких цепей и участки, определяющие комплементарность (CDR), в составе антител, а также способы получения и применения этих антител.Specific binding agents are disclosed, such as fully human antibodies that bind angiopoietin-2. Also disclosed are fragments of heavy chains, fragments of light chains, and regions that determine complementarity (CDR) in the composition of antibodies, as well as methods for producing and using these antibodies.

EA200700876A 2004-10-19 2005-10-19 Angiopoetin-2 specific binding agents EA011866B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (2)

Publication Number Publication Date
EA200700876A1 true EA200700876A1 (en) 2007-10-26
EA011866B1 EA011866B1 (en) 2009-06-30

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700876A EA011866B1 (en) 2004-10-19 2005-10-19 Angiopoetin-2 specific binding agents

Country Status (10)

Country Link
JP (2) JP2008520188A (en)
CN (1) CN101495513B (en)
BR (1) BRPI0518209A (en)
EA (1) EA011866B1 (en)
IL (1) IL182279A0 (en)
MA (1) MA29015B1 (en)
MX (1) MX2007004247A (en)
RU (2) RU2404992C2 (en)
SG (1) SG156668A1 (en)
ZA (1) ZA200704020B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2404992C2 (en) * 2004-10-19 2010-11-27 Эмджен Инк. Angiopoietin-2-specific coupling agents
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma High Affinity Human Antibodies to Human Angiopoietin-2
EA022546B1 (en) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Method for inhibiting growth of ehrlich carcinoma in laboratory animal
ES2757473T3 (en) * 2011-09-30 2020-04-29 Dana Farber Cancer Inst Inc Therapeutic peptides comprising antibodies that bind to MHC class I polypeptide-related sequence A (MICA)
NZ627859A (en) * 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (en) * 2014-05-19 2016-09-21 Lilly Co Eli ANTIBODIES ANG2
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
PL3263106T3 (en) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR20170122809A (en) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer
WO2016204193A1 (en) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ Anticancer agent
CN106512006A (en) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Application of ANGPT2 secretion inhibitor to preparation of medicine for treating hemangiomas
CN106075448A (en) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 ANGPT2 inhibitor is used for treating the application in angiomatous medicine in preparation
CN109096368B (en) * 2018-09-30 2021-07-20 华南理工大学 Polypeptide with antioxidant and liver protecting activities, gene for encoding polypeptide, preparation method and application thereof
KR102527315B1 (en) * 2019-02-25 2023-05-03 주식회사 파멥신 Anti- Ang2 antibody and Use Thereof
CN112126671B (en) * 2020-08-18 2021-08-31 中山大学附属第五医院 Application of streptococcus agalactiae streptococcus agalactiae in treating endometriosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514434A (en) * 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
DK2332523T4 (en) * 2001-10-12 2022-02-21 Aquestive Therapeutics Inc Uniform films for rapid-dissolution dosage form containing taste-masking preparations
RU2404992C2 (en) * 2004-10-19 2010-11-27 Эмджен Инк. Angiopoietin-2-specific coupling agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
US9534007B2 (en) 2012-12-21 2017-01-03 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity

Also Published As

Publication number Publication date
CN101495513A (en) 2009-07-29
RU2007118670A (en) 2008-12-27
JP2011207882A (en) 2011-10-20
BRPI0518209A (en) 2008-11-04
EA011866B1 (en) 2009-06-30
ZA200704020B (en) 2008-06-25
RU2404992C2 (en) 2010-11-27
JP2008520188A (en) 2008-06-19
CN101495513B (en) 2014-08-06
MX2007004247A (en) 2007-06-12
IL182279A0 (en) 2007-07-24
MA29015B1 (en) 2007-11-01
SG156668A1 (en) 2009-11-26
RU2010132956A (en) 2012-02-10

Similar Documents

Publication Publication Date Title
EA200700876A1 (en) AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2
RS28904A (en) Angiopoietin-2 specific binding agents
EA200400526A1 (en) AGENTS SPECIFICALLY CONNECTING WITH HUMAN ANGIOPOETIN-2
EA201001335A1 (en) ANTIBODIES DIRECTED AGAINST ANGIOPOETHINA-1 AND ANGIOPOETINA-2 AND THEIR APPLICATION
EA201070888A1 (en) ANTIBODIES AND THEIR DERIVATIVES
NO2017032I1 (en) bezlotoksumab
EA200800812A1 (en) Antibody Anti-CD3 Compositions
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
MX342413B (en) Antibodies to matrix metalloproteinase 9.
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
EP2425850A3 (en) Bispecific single chain FV antibody molecules and methods of use thereof
EA200802168A1 (en) HUMANIZED ANTIBODY TO C-KIT
TW200617025A (en) Il-17 antagonistic antibodies
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
TW200635946A (en) Binding proteins specific for human matriptase
EA200801172A1 (en) LIGANDS HAVING A SPECIFICITY OF BINDING WITH RESPECT TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR (EGFR) AND / OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), AND THEIR APPLICATION
EA201491575A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
EP2192132A3 (en) Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
WO2006058890A3 (en) Method of producing antibodies
MX360580B (en) Human anti-alpha-synuclein autoantibodies.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU